Best Biopharma Outsourcing Companies in New York, United States
The 147 best Biopharma Outsourcing companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cambrian BioPharma.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cambrian BioPharma Developer of medicines and therapies | $211M | 36 mo ago | 48 | 2019 | James Peyer Founder & CEO | WebflowYouTubeMicrosoft 365+8 | — | 1 launch |
| 2 | OnCusp CRO offering clinical development services for oncology drugs | $139M | 29 mo ago | 15 | 2021 | Eric Slosberg Co-Founder | — | — | — |
| 3 | Creative Peptides Provider of bioactive peptides, peptide synthesis, and GMP manufacturing services | $59M | 139 mo ago | — | 2004 | Caroline Miller CEO | Cart FunctionalityMicrosoft ASP.NETBootstrap+13 | 42 patents Patents concentrated in health & consumer products | — |
| 4 | Advion Mass spectrometry, chromatography, and purification solutions for scientific advancement | $46M | 143 mo ago | 54 | 1993 | — | WordPressMySQLPHP+18 | 32 patents Ionization and surface sampling interfaces for mass spectrometry analysis. | — |
| 5 | Liberation Labs CRO focused on providing fermentation products manufacturing and commercialisation services 22Funding top 29%Talent top 38%Growth bottom 42%Global bottom 37% All 7 signals ▾Fundingtop 29% Talenttop 38% Growthbottom 42% Globalbottom 37% Techbottom 30% Newsbottom 21% Marketbottom 17% Funding: Raised $36.0M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $36M | 16 mo ago | 13 | 2022 | Etan Bendheim Co-Founder & Chief Business Officer | WordPressMySQLPHP+15 | — | — |
| 6 | SterRx FDA registered CMO offering its services for sterile (503b {compounded}) drug products manufacturing | $18M | 104 mo ago | 76 | 2013 | — | — | — | — |
| 7 | Orange Grove Bio LLC Provider of preclinical development services | $17M | 45 mo ago | 55 | 2019 | Lutz Giebel Co-Founder | — | — | — |
| 8 | CPSI Biotech Innovating cryobiology and medical device engineering for life science advancements | $13M | 25 mo ago | — | 2003 | — | — | — | — |
| 9 | TechnoVax Innovative vaccine technologies for groundbreaking clinical solutions, optimized effectiveness, and safety | $9M | 70 mo ago | 9 | 2004 | George Martin Co-Founder & CTO | — | 53 patents Patents concentrated in health & consumer products | — |
| 10 | PsychoGenics Preclinical CRO with specific focus on CNS and orphan disorders. | $7M | 21 mo ago | 124 124 → 166 (+34%) | 1999 | — | JavaBootstrapApache HTTP Server+6 | 84 patents Patents concentrated in health & consumer products | — |
| 11 | Aphena Pharma Pharmaceutical manufacturing and packaging solutions for diverse healthcare sectors | $6M | 144 mo ago | 620 | 2002 | Kevin Kerchner ex-CEO | HubSpot CMS HubGSAPcore-js+15 | — | — |
| 12 | iCardiac Technologies Company offering core laboratory services mainly for cardiac safety testing and respiratory diseases | $4M | 147 mo ago | 200 | 2006 | — | — | — | — |
| 13 | KPS Life CRO offering full and functional services for clinical development | $4M | 9 mo ago | 101 | 2006 | David Kelly Founder & CEO | WordPress Block EditorWordPressApple iCloud Mail+29 | — | — |
| 14 | Ichor Life Sciences Provider of premium laboratory CRO services to biotechnology and research organizations | $3M | 45 mo ago | 43 | 2013 | Kelsey Moody Chief Executive Officer | — | — | — |
| 15 | Mirimus Accelerating drug discovery with precision preclinical services and innovative disease models | $2M | 21 mo ago | 85 | 2011 | Prem Premsrirut President/CEO | WebflowVultrSwiper+15 | 21 patents RNAi therapeutics: engineered amiRNA/miRNA design, regulation, and interferon decoy applications | — |
| 16 | NeuroTrax Provider of computerised brain wellness monitoring services | $2M | 222 mo ago | 6 | 2000 | — | anime.jsUIKitBootstrap+10 | 5 patents Patents concentrated in health & consumer products | 1 launch |
| 17 | iFyber Preclinical CRO providing custom research services for medical devices and specialty textiles | $1M | 69 mo ago | 24 | 2009 | — | WordPressMySQLPHP+19 | 3 patents Patents concentrated in computing, sensing & instrumentation | — |
| 18 | NexGenix Pharmaceuticals CRO focused on drug discovery and development of targeted therapies for cancer | $1M | 34 mo ago | 4 | 2003 | — | — | — | — |
| 19 | Alzheimer's Drug Discovery Foundation aims to discover drugs to prevent, treat, and cure alzheimer's disease | $1M | 186 mo ago | — | 1998 | Ronald Lauder Co-Founder | ExpressionEnginePHPUbuntu+22 | — | 1 launch · 1 partnership |
| 20 | Curia Provider of drug research & development, testing, and consulting services | $1M | 61 mo ago | 1,918 | 1991 | — | WordPress Block EditorWordPressApple iCloud Mail+34 | 22 patents Patents concentrated in health & consumer products | — |
| 21 | Athenex Provides manufacturing and support services for small molecules and biologics | $1M | 162 mo ago | — | 2010 | Stephen Panaro Founder | — | 120 patents Patents concentrated in health & consumer products | — |
| 22 | Epikast Provider of medical affairs and market access services | $700K | 4 mo ago | — | 2022 | Stelios Papadopoulos Co-Founder | WordPressMySQLPHP+24 | — | — |
| 23 | Humonix Biosciences CRO focused on ophthalmic drugs development services | $600K | 134 mo ago | 10 | 2014 | Karen Torrejon Co-Founder and CEO | — | — | — |
| 24 | True North Life Sciences Provider of business strategy, marketing, and other services for drug development industries | $548K | 61 mo ago | — | 2015 | David Battleman Founder | — | — | — |
| 25 | Syntactx CRO that assists medical device, pharmaceutical, and diagnostic laboratory companies with the design and… | $512K | 72 mo ago | 90 | 2010 | — | — | — | — |
| 26 | L2P Research Preclinical research organization specializing in oncology animal models and offering a wide range of… | $319K | 32 mo ago | 12 | 2015 | Suresh Anaganti Founder & CEO | — | — | — |
| 27 | Inizio Provider of commercialization and clinical development solutions for life science companies | $255K | 45 mo ago | — | 2022 | Paul Taaffe CEO | WordPressApple iCloud MailMySQL+34 | — | 1 partnership · 3 awards |
| 28 | Biosight Provider of imaging-focused clinical trial support services | $225K | 101 mo ago | — | 2018 | Manus Donahue Founder & CEO | — | — | — |
| 29 | Generable Bayesian computational oncology, providing Stan-based modeling, optimization, and a HIPAA-compliant cloud | $120K | 108 mo ago | 4 | 2016 | Eric Novik Co-Founder & CEO | — | — | — |
| 30 | Holobeam Technologies CRO focused on oncology drugs development services | $72K | 90 mo ago | 30 | 2018 | Gene Dolgoff Founder | — | — | — |
| 31 | Clinilabs A full-service contract research organisation | — | 15 mo ago | 195 | 2001 | — | WordPressMySQLPHP+29 | 13 patents Digital platforms for online clinical trial recruitment, patient referral, and efficacy data reporting | 1 job opening · 1 partnership |
| 32 | Pfizer Provider of pharmaceutical products for multiple disease treatments | — | 35 mo ago | — | 1849 | Sai Boddu Director | DrupalApple iCloud MailPHP+25 | — | — |
Top 12 Biopharma Outsourcing companies in New York
#1
Series C · New York City, New York · founded 2022 · 13 employees$36Mraised▾
CRO focused on providing fermentation products manufacturing and commercialisation services
- Jan 2025Series C$52M
- Oct 2024Grant (prize money)$1.4M
- Apr 2024Series A$19M
- Nov 2023Conventional Debt$25M
#2
Seed · New York City, New York · founded 2006 · 101 employees$3.5Mraised▾
Kellman Pharmaceutical Services (KPS) is a full service CRO and a functional service provider offering its services to the pharmaceutical, biotech, and medical device industries. They offer their services for clinical operations, quality assurance, data management, drug safety and regulatory affairs. They can also provide qualified clinical resources to be assigned to specific outsourced tasks such as clinical monitoring, project management, and others. They offer their services for Phase I - IV clinical trials and have therapeutic experience in oncology, CNS, hematology, infectious disease, rare and ultra-rare diseases, vaccines, pediatrics, women's health, endocrinology and several others.
- Sep 2025Seed$1.2M
- Jun 2025Seed$2.3M
#3
Seed · New York, New York · founded 2022$700Kraised▾
Provider of medical affairs and market access services
- Jan 2026Seed$700K
#4
Series A · New York City, New York · founded 2021 · 15 employees$139Mraised▾
CRO offering clinical development services for oncology drugs
- Jan 2024Series A$100M
- Seed—
#5
Funding Raised · Tarrytown, New York · founded 1999 · 124 employees$7Mraised▾
Psychogenics offers drug discovery capabilities for companies focusing on CNS and orphan disorders psychiatric and neurodegenerative disorders, pain and inflammation, spinal cord and traumatic brain injury. PsychoGenics' capabilities include behavioral testing, electrophysiology, molecular biology, microdialysis and a variety of in-licensed transgenic mouse models. PsychoGenics’ technologies have been developed to facilitate high throughput, in vivo, compound screening. It facilitates drug discovery by combining expertise in behavioral neurobiology, bioinformatics and behavioral testing platforms, that can rapidly screen compound libraries for CNS activity.
- Aug 2024Grant (prize money)$3M
- Aug 2024Grant (prize money)$560.6K
- Aug 2023Grant (prize money)$999.9K
- Feb 2010Grant (prize money)$366.7K
#6
Series C · Brooklyn, New York · founded 2019 · 48 employees$211.5Mraised▾
Developer of medicines and therapies
- Jun 2023Series C$23M
- Oct 2021Series C$100M
- May 2021Series C$28.4M
- Jan 2020Series C$60M
#7
Funding Raised · Owego, New York · founded 2003$13.1Mraised▾
Innovating cryobiology and medical device engineering for life science advancements. The company is a technology development company focused on cryobiology and medical device engineering. It develops novel technologies and designs innovative life science research products and cryo-medical devices. The company's mission is to advance applications in cancer, cardiovascular disease treatments, and cell therapy bioprocessing. They challenge current scientific dogma to elevate basic and clinical sciences. The company is committed to efficient innovation and contract research services, developing technologies, devices, and intellectual property for commercialization ventures, licensing, or sales. Their approach integrates life science fundamentals, engineering research, and an innovative team to achieve results. The company develops technologies and devices for diverse clinical and research applications.
- May 2024Grant (prize money)$306K
- Sep 2022Grant (prize money)$310.4K
- Sep 2019Grant (prize money)$348K
- Sep 2018Grant (prize money)$300.1K
#8
Series A · Cold Spring Harbor, New York · founded 2011 · 85 employees$2Mraised▾
Accelerating drug discovery with precision preclinical services and innovative disease models. This biotech and preclinical CRO delivers scalable, high-precision solutions to accelerate drug discovery and bring new therapies closer to patients. They provide high-quality animal and cell models for critical in vivo studies, empowering researchers to gain precise control over in vivo gene expression. Services include preclinical drug discovery, RNAi services, 2D/3D in vitro models, and customized animal models. They drive advancements in human health by designing accurate, translatable, genetically engineered animal and cellular models with adjustable activity, covering all levels from complete knockout to overexpression and modification of endogenous loci. They unlock the therapeutic potential of RNA Interference (RNAi) and accelerate the development of new therapies for the world’s most challenging diseases. They recreate the architecture and physiology of organs with clinically relevant 3D tissue cultures developed from human induced pluripotent stem cells (iPSCs) or mouse tissues.
- Sep 2024Grant (prize money)$350K
- May 2023Grant (prize money)$397.9K
- Aug 2018Grant (prize money)$2.3M
- Aug 2014Grant (prize money)$189K
#9
Series B · New York City, New York · founded 2019 · 55 employees$16.6Mraised▾
Provider of preclinical development services
- Aug 2022Series B$16.6M
#10
Series C · Shirley, New York · founded 2004$59Mraised▾
Provider of bioactive peptides, peptide synthesis, and GMP manufacturing services. The company's product includes therapeutic peptides, cosmetic peptides, functional peptides, catalog peptides, and amino acids. The company also provides services in peptide modification, peptide synthesis, GMP, peptide analysis, and protein glycosylation.
- Nov 2014Series C$33.2M
- Mar 2012Convertible Debt$8.8M
- Aug 2010Series B$14M
- Oct 2008Series A$2.9M
#11
Acquired · Ithaca, New York · founded 1993 · 54 employees$45.6Mraised▾
Mass spectrometry, chromatography, and purification solutions for scientific advancement. The company delivers tailored solutions for identification, quantification, and purification needs. Their portfolio includes instruments, consumables, reagents, and scientific expertise. They offer media, columns, accessories, and instruments for flash chromatography, preparative (U)HPLC, analytical (U)HPLC, mass spectrometry, and ICP-MS, coupled with intelligent apps and software. They serve academic, pharmaceutical, biopharmaceutical, and clinical clients worldwide. The company focuses on purpose-built products that improve workflows for the life science industry. They provide solutions for reaction monitoring, compound identification, cannabis and hemp testing, protein and peptide analysis, and elemental analysis. They offer resources like application notes and webinars. The company is dedicated to providing best-in-class service and support.
- Jun 2014Series D$1.5M
- Jun 2014Conventional Debt—
- Nov 2013Series D$9.2M
- Aug 2007Series C$9.1M
#12
Seed · Manhattan, New York · founded 2013 · 43 employees$3.5Mraised▾
Ichor Life Sciences is a company that provides premium laboratory CRO services to biotechnology and research organizations. They aim to support people in living longer and healthier lives.
- Sep 2022Grant (prize money)$299.7K
- Sep 2018Seed$1.5M
- Jul 2016Seed$600K
- Mar 2016Seed$1.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.